| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Mirum Pharmaceuticals (NASDAQ:MIRM) through any online brokerage.
Other companies in Mirum Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Mirum Pharmaceuticals has a consensus price target of $119.00.
The stock price for Mirum Pharmaceuticals (NASDAQ: MIRM) is $79.91 last updated October 13, 2026 at 5:27 PM EDT.
There are no upcoming dividends for Mirum Pharmaceuticals.
Mirum Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Mirum Pharmaceuticals.
Mirum Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
